Alkermes plc (ALKS)
ALKS Stock Price Chart
Explore Alkermes plc interactive price chart. Choose custom timeframes to analyze ALKS price movements and trends.
ALKS Company Profile
Discover essential business fundamentals and corporate details for Alkermes plc (ALKS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jul 1991
Employees
2.10k
Website
http://www.alkermes.comCEO
Richard F. Pops
Description
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Financial Timeline
Browse a chronological timeline of Alkermes plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Jul 2026
EPS estimate is -$0.04, while revenue estimate is $458.72m.
Earnings released on 5 May 2026
EPS came in at -$0.40 surpassing the estimated -$0.57 by +29.82%, while revenue for the quarter reached $392.91m , beating expectations by +8.22%.
Earnings released on 25 Feb 2026
EPS came in at $0.34 falling short of the estimated $0.43 by -20.93%, while revenue for the quarter reached $384.55m , beating expectations by +1.48%.
Earnings released on 28 Oct 2025
EPS came in at $0.49 surpassing the estimated $0.42 by +16.67%, while revenue for the quarter reached $394.19m , beating expectations by +3.76%.
Earnings released on 29 Jul 2025
EPS came in at $0.52 surpassing the estimated $0.41 by +26.83%, while revenue for the quarter reached $390.66m , beating expectations by +10.20%.
Earnings released on 1 May 2025
EPS came in at $0.13 falling short of the estimated $0.25 by -48.92%, while revenue for the quarter reached $306.51m , beating expectations by +1.19%.
Earnings released on 12 Feb 2025
EPS came in at $1.04 surpassing the estimated $0.81 by +28.40%, while revenue for the quarter reached $429.99m , beating expectations by +13.33%.
Earnings released on 24 Oct 2024
EPS came in at $0.72 falling short of the estimated $0.74 by -2.70%, while revenue for the quarter reached $378.14m , missing expectations by -0.84%.
Earnings released on 24 Jul 2024
EPS came in at $0.70 matching the estimated $0.70, while revenue for the quarter reached $399.13m , beating expectations by +4.26%.
Earnings released on 1 May 2024
EPS came in at $0.44 falling short of the estimated $0.59 by -25.42%, while revenue for the quarter reached $350.37m , missing expectations by -10.93%.
Earnings released on 15 Feb 2024
EPS came in at $0.48 surpassing the estimated $0.46 by +4.35%, while revenue for the quarter reached $377.48m , beating expectations by +0.13%.
Earnings released on 25 Oct 2023
EPS came in at $0.64 surpassing the estimated $0.44 by +45.45%, while revenue for the quarter reached $380.94m , beating expectations by +5.19%.
Earnings released on 26 Jul 2023
EPS came in at $0.55 surpassing the estimated $0.48 by +14.58%, while revenue for the quarter reached $617.40m , beating expectations by +69.68%.
Earnings released on 26 Apr 2023
EPS came in at $0.01 surpassing the estimated $0.00 by +173.97%, while revenue for the quarter reached $287.60m , missing expectations by -50.49%.
Earnings released on 16 Feb 2023
EPS came in at $0.14 surpassing the estimated $0.05 by +180.00%, while revenue for the quarter reached $304.67m , beating expectations by +9.32%.
Earnings released on 2 Nov 2022
EPS came in at $0.02 falling short of the estimated $0.03 by -34.06%, while revenue for the quarter reached $252.36m , missing expectations by -7.02%.
Earnings released on 27 Jul 2022
EPS came in at $0.06 surpassing the estimated $0.01 by +740.34%, while revenue for the quarter reached $276.22m , beating expectations by +2.70%.
Earnings released on 27 Apr 2022
EPS came in at $0.12 surpassing the estimated $0.01 by +1.07k%, while revenue for the quarter reached $278.55m , beating expectations by +8.80%.
Earnings released on 16 Feb 2022
EPS came in at $0.23 surpassing the estimated $0.13 by +76.92%, while revenue for the quarter reached $324.46m , beating expectations by +5.84%.
Earnings released on 27 Oct 2021
EPS came in at $0.14 surpassing the estimated $0.08 by +75.00%, while revenue for the quarter reached $294.14m , beating expectations by +21.21%.
Earnings released on 28 Jul 2021
EPS came in at $0.30 surpassing the estimated $0.12 by +150.00%, while revenue for the quarter reached $303.72m , beating expectations by +1.34%.
ALKS Stock Performance
Access detailed ALKS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
